Clinical experience of capecitabine in metastatic breast cancer

European Journal of Cancer

Volumn 38, Issue SUPPL. 2, 2002, Pages 10-14

  O'Shaughnessy, J ^a  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Anthracyclines; Breast cancer; Capecitabine; Fluoropyrimidines; Paclitaxel

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG ACTIVATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HAND FOOT SYNDROME; HUMAN; METASTASIS; POSTMENOPAUSE; PRIORITY JOURNAL;

EID: 0036179297     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0959-8049(01)00416-6     Document Type: Article

References (10)

1. Current management of metastatic breast cancer
2. Salvage chemotherapy of breast cancer
3. Patient preferences for oral versus intravenous palliative chemotherapy
4. A study of quality of life in cancer patients receiving palliative chemotherapy
5. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer
6. Can patients with metastatic breast cancer (MBC) pretreated with cyclophosphamide (C), anthracyclines (A) or Taxol (Tax) respond to infusions of 5-FU (FUI)? Rationale for FUI-containing chemotherapy (CT) regimens
7. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer
8. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast cancer patients
9. A randomized phase II study of Xeloda™ (capecitabine) vs. paclitaxel in breast cancer patients failing previous anthracycline therapy
10. Randomized, open-label, phase II trial of oral capecitabine (Xeloda®) versus a reference arm of intravenous CMF (cyclophosphamide, methotrexate, 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer